These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15449549)

  • 21. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
    Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV
    Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial.
    Abid S; Jafri W; Hamid S; Salih M; Azam Z; Mumtaz K; Shah HA; Abbas Z
    Am J Gastroenterol; 2009 Mar; 104(3):617-23. PubMed ID: 19223890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients.
    Salerno F; Borroni G; Lorenzano E; Solenghi D; Cazzaniga M; Bissoli F; Ceriani R; deFranchis R
    Hepatology; 1996 May; 23(5):1135-40. PubMed ID: 8621145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis.
    Mountokalakis T; Kallivretakis N; Mayopoulou-Symvoulidou D; Karvountzis G; Tolis G
    Nephrol Dial Transplant; 1988; 3(5):604-7. PubMed ID: 3146715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure.
    Ginès A; Salmerón JM; Ginès P; Arroyo V; Jiménez W; Rivera F; Rodés J
    J Hepatol; 1993 Feb; 17(2):220-6. PubMed ID: 8445236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial.
    Pollo-Flores P; Soldan M; Santos UC; Kunz DG; Mattos DE; da Silva AC; Marchiori RC; Rezende GF
    Dig Liver Dis; 2015 Nov; 47(11):957-63. PubMed ID: 26321186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of somatostatin on renal function in cirrhosis.
    Ginès A; Salmerón JM; Ginès P; Jiménez W; Saló J; Piera C; Clària J; Rivera F; Arroyo V; Rodés J
    Gastroenterology; 1992 Dec; 103(6):1868-74. PubMed ID: 1360435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis.
    Sabbà C; Buonamico P; Vendemiale G; Berardi E; Antonica G; Palmieri V; Merkel C; Palasciano G
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):163-9. PubMed ID: 11246616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis.
    Chan CC; Lee FY; Wang SS; Chang FY; Lin HC; Lin HJ; Chu CJ; Wu SL; Tai CC; Lee SD
    Clin Sci (Lond); 1998 Apr; 94(4):367-71. PubMed ID: 9640342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension.
    Chandok N; Kamath PS; Blei A; Bosch J; Carey W; Grace N; Kowdley KV; Benner K; Groszmann RJ
    Aliment Pharmacol Ther; 2012 Apr; 35(8):904-12. PubMed ID: 22380529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Emergency medical treatment of portal hypertension].
    Heresbach D; Bretagne JF; Gosselin M
    Presse Med; 1995 Sep; 24(28):1311-4. PubMed ID: 7501625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time profile of the haemodynamic effects of terlipressin in portal hypertension.
    Escorsell A; Bandi JC; Moitinho E; Feu F; García-Pagan JC; Bosch J; Rodés J
    J Hepatol; 1997 Mar; 26(3):621-7. PubMed ID: 9075670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic venous pressure gradient measurement in patients with liver cirrhosis: a correlation with disease severity and variceal bleeding.
    Silkauskaite V; Pranculis A; Mitraite D; Jonaitis L; Petrenkiene V; Kupcinskas L
    Medicina (Kaunas); 2009; 45(1):8-13. PubMed ID: 19223700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis.
    Lin HC; Yang YY; Hou MC; Huang YT; Lee WC; Lee FY; Chang FY; Lee SD
    Scand J Gastroenterol; 2002 Apr; 37(4):482-7. PubMed ID: 11989841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J; Iwakiri Y
    Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Somatostatin, octreotide and portal hypertension].
    Silvain C; Besson I; Beauchant M
    Gastroenterol Clin Biol; 1994; 18(8-9):761-6. PubMed ID: 7875447
    [No Abstract]   [Full Text] [Related]  

  • 37. Octreotide lowers gastric mucosal blood flow in normal and portal hypertensive stomachs.
    Clarke DL; McKune A; Thomson SR
    Surg Endosc; 2003 Oct; 17(10):1570-2. PubMed ID: 12874677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver.
    Gentilini P; Romanelli RG; La Villa G; Maggiore Q; Pesciullesi E; Cappelli G; Casini Raggi V; Foschi M; Marra F; Pinzani M
    Gastroenterology; 1993 Feb; 104(2):588-94. PubMed ID: 8425702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study.
    McCormick PA; Biagini MR; Dick R; Greenslade L; Chin J; Cardin F; Wagstaff D; McIntyre N; Burroughs AK
    Hepatology; 1992 Nov; 16(5):1180-6. PubMed ID: 1427656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension.
    Yang JF; Wu XJ; Li JS; Cao JM; Han JM
    Eur J Gastroenterol Hepatol; 2005 Jan; 17(1):53-7. PubMed ID: 15647641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.